title: Target organ damage and control of cardiovascular risk factors in hypertensive patients. Evidence from the multicenter ESTher registry.
abstract: OBJECTIVE
  This study investigated the incidence of hypertensive target organ damage (TOD), control of cardiovascular risk factors, and the short-term prognosis in hypertensive patients under contemporary guideline-oriented therapy.
  
  
  METHODS
  A total of 1,377 consecutive patients (mean age 58.2 ± 9.9 years, 82.2 % male) with arterial hypertension were included in the ESTher (Endorganschäden, Therapie und Verlauf - target organ damage, therapy, and course) registry at 15 rehabilitation clinics within the framework of the National Genome Research Network. Cardiovascular risk factors, medication, comorbidities, and glomerular filtration rate (GFR) were assessed. Left ventricular hypertrophy (LVH), left ventricular mass (LVM), left ventricular mass index (LVMI), and left ventricular ejection fraction (LVEF) were determined by two-dimensional echocardiography. The mean follow-up was 513 ± 159 days. Changes in continuous parameters were tested by the t test, changes in discrete characteristics are presented by means of transition tables and tested with the McNemar test.
  
  
  RESULTS
  The mean LVEF was 59.3 ± 9.9 %, both mean LVM (238.6 ± 101.5 g) and LVMI (54.0 ± 23.6 g/m(2.7)) were increased while relative wall thickness (RWT, 0.46 ± 0.18) indicated the presence of concentric LVH. Of the patients, 10.2 % displayed renal dysfunction (estimated GFR < 60 ml/min/1.73 m(2)). The 1.5-year overall mortality was 1.2 %. Compared with discharge, at follow-up the proportion of patients with blood pressure (BP) values < 140/90 mmHg decreased from 68.7 % to 55.0 % (p < 0.001) and with low-density lipoprotein (LDL) values < 100 mg/dl from 62.6 % to 38.1 % (p < 0.001). At follow-up significantly more patients displayed a GFR value of < 60 ml/min/1.73 m(2) (10.2 % vs. 16.0 %, p < 0.001).
  
  
  CONCLUSIONS
  A significant proportion of hypertensive rehabilitation participants displayed TOD including LVH and renal dysfunction. Even after stringent BP reduction, a considerable increase in nephropathy could be found after 18 months.
authors: Cardiological Outpatient Clinic Am Park Sanssouci Potsdam, Zimmerstrasse 7a, 14471, Potsdam, Germany, rona.reibis@hotmail.de.
authors: R K
authors: RK
authors: Reibis
authors: M
authors: M
authors: Huber
authors: M
authors: M
authors: Karoff
authors: W
authors: W
authors: Kamke
authors: R
authors: R
authors: Kreutz
authors: K
authors: K
authors: Wegscheider
authors: H
authors: H
authors: Völler
mesh_terms: D015897:Comorbidity; D019317:Evidence-Based Medicine; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000401:mortality*; D017379:Hypertrophy, Left Ventricular / Q000401:mortality*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D058958:Organs at Risk; D012042:Registries; D051437:Renal Insufficiency / Q000401:mortality*; D012307:Risk Factors; D015996:Survival Rate; D018487:Ventricular Dysfunction, Left / Q000401:mortality*
references: Eur J Intern Med. 2013 Mar;24(2):145-50
references: 23182629
references: Lancet. 2005 Jan 15-21;365(9455):217-23
references: 15652604
references: Eur Heart J. 2013 Jul;34(28):2159-219
references: 23771844
references: Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
references: 11904577
references: Hypertension. 2011 Oct;58(4):566-72
references: 21825231
references: Clin Res Cardiol. 2011 Jun;100(6):483-91
references: 21207045
references: Eur J Prev Cardiol. 2014 Aug;21(8):980-8
references: 23335655
references: Eur J Cardiovasc Prev Rehabil. 2007 Feb;14 (1):18-27
references: 17301623
references: J Hypertens. 2003 Jun;21(6):1011-53
references: 12777938
references: J Am Geriatr Soc. 1985 Apr;33(4):278-85
references: 3989190
references: Eur J Cardiovasc Prev Rehabil. 2010 Aug;17(4):410-8
references: 20300001
references: Lancet. 2010 Jun 12;375(9731):2073-81
references: 20483451
references: Eur J Prev Cardiol. 2014 Jun;21(6):664-81
references: 22718797
references: BMC Fam Pract. 2011 Jul 14;12:75
references: 21756310
references: J Nephrol. 2014 Dec;27(6):635-41
references: 24643437
references: Eur J Echocardiogr. 2006 Mar;7(2):79-108
references: 16458610
references: Ann Intern Med. 2003 Jul 15;139(2):137-47
references: 12859163
references: J Am Coll Cardiol. 1992 Jun;19(7):1550-8
references: 1534335
references: Eur J Prev Cardiol. 2012 Jun;19(3):515-22
references: 21450575
references: Eur J Cardiovasc Prev Rehabil. 2009 Feb;16(1):114-6
references: 19238000
references: Eur Heart J. 2010 Aug;31(16):1967-74
references: 20643803
references: Eur Heart J. 2011 Jul;32(13):1599-604
references: 21444366
references: Eur J Prev Cardiol. 2014 Feb;21(2):163-71
references: 23180866
references: J Am Soc Nephrol. 2009 Dec;20(12):2617-24
references: 19892932
references: Eur J Cardiovasc Prev Rehabil. 2011 Aug;18(4):680-1
references: 22028499
references: Eur Heart J. 2008 Dec;29(24):3052-60
references: 18996953
references: Hypertens Res. 2011 Oct;34(10):1106-10
references: 21796127
references: BMJ. 2003 Jun 28;326(7404):1423
references: 12829554
references: J Med Assoc Thai. 2012 Apr;95(4):508-18
references: 22612004
references: J Am Soc Echocardiogr. 2004 Oct;17 (10 ):1086-119
references: 15452478
references: J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S104-8
references: 16565230
references: Am J Cardiol. 2011 Oct 1;108(7):992-6
references: 21784383
references: Hypertension. 2009 Jan;53(1):28-34
references: 19015402
references: Curr Opin Nephrol Hypertens. 2011 Mar;20(2):113-7
references: 21245763
references: N Engl J Med. 2008 Dec 4;359(23):2417-28
references: 19052124